Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMLSG 30-18: CPX-351 versus standard intensive chemotherapy in newly diagnosed AML with intermediate- or adverse-risk genetics
2018-002678-34Phase 3Active
- Sponsor
- University Hospital Ulm
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cytarabine and daunorubicin in acute myeloid leukemia (AML) (2 arms), sponsored by University Hospital Ulm. Primary endpoint: Overall survival. Started Apr 2019; status: active.
02
Drugs
cytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-002678-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002678-34.